On March 18, 2026 SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, reported an abstract for iza-bren (izalontamab brengitecan), a potentially first-in-class EGFRxHER3 bispecific antibody drug conjugate (ADC), will be presented at the European Lung Cancer Congress (ELCC 2026) taking place March 25 – 28 in Copenhagen, Denmark. Iza-bren is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement in territories outside of China.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The safety and efficacy results of iza-bren in combination with serplulimab in treatment-naive patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) will be presented at ELCC. The data highlight the continued progress of iza-bren clinical development in China and build upon the previously reported clinical activity in lung, breast, and bladder cancer patients at ASCO (Free ASCO Whitepaper), ESMO (Free ESMO Whitepaper), WCLC, and SABCS in 2023, 2024 and 2025.
"The data being presented at ELCC highlight the continued clinical progress of iza-bren and its potential as a novel treatment approach for patients with difficult-to-treat lung cancers," said Jonathan Cheng, M.D., Chief Medical Officer of SystImmune. "We are encouraged by the safety and efficacy signals observed with iza-bren in combination with serplulimab in treatment-naïve patients with extensive-stage small cell lung cancer. These findings support further exploration of iza-bren–based combinations in earlier lines of therapy as we work to expand therapeutic options for patients with aggressive lung malignancies."
Details of the presentation at ELCC are below:
Phase II Study of iza-bren (BL-B01D1) in Combination with Serplulimab in Patients with Small Cell Lung Cancer (SCLC)
Session Title: Proffered Paper Session 1
Presentation: 408O
Speaker: Fei Zhou (Shanghai, China)
Session Date & Time: Wednesday, March 25th, 2026, 2:45 PM-4:15 PM CET
About iza-bren
SystImmune, in collaboration with BMS outside of China, is developing iza-bren (BL-B01D1), a bispecific antibody-drug conjugate (ADC) that targets both EGFR and HER3, which are highly expressed in various epithelial cancers and are known to be associated with cancer cell proliferation and survival. Iza-bren’s dual mechanism of action blocks EGFR and HER3 signals to cancer cells, reducing proliferation and survival signals. In addition, upon antibody mediated internalization, iza-bren’s therapeutic novel Topo1i payload is released causing cytotoxic stress that leads to cancer cell death.
(Press release, SystImmune, MAR 18, 2026, View Source [SID1234663715])